Hammering the point home: Serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India

Evidence-Based Medicine

Volumn 17, Issue 2, 2012, Pages 58-59

  Menzies, Dick ^a  

^a Montreal Chest ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; HUMORAL IMMUNITY; INDIA; LUNG TUBERCULOSIS; MICROSCOPY; MORBIDITY; MORTALITY; NOTE; SENSITIVITY AND SPECIFICITY; SEROLOGY; SMEAR;

EID: 84859444619     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed.2011.100291     Document Type: Note

References (4)

1. Steingart KR, Henry M, Laal S, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax 2007;62:911-18. (Pubitemid 47598357)
2. Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011;8:e1001062.
3. World Health Organization (2011) Policy Statement. Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis. Geneva, Switzerland: WHO, 2011.
4. Pai M, Minion J, Steingart K, et al. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010;16:271-84.